Compare SGC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGC | LUNG |
|---|---|---|
| Founded | 1920 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.8M | 97.1M |
| IPO Year | 1994 | 2020 |
| Metric | SGC | LUNG |
|---|---|---|
| Price | $12.42 | $1.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $16.00 | $5.38 |
| AVG Volume (30 Days) | 33.7K | ★ 395.5K |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | ★ 4.93% | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $566,184,000.00 | $90,497,000.00 |
| Revenue This Year | $3.23 | $2.48 |
| Revenue Next Year | $3.82 | $18.46 |
| P/E Ratio | $88.50 | ★ N/A |
| Revenue Growth | 0.09 | ★ 8.01 |
| 52 Week Low | $8.30 | $1.13 |
| 52 Week High | $14.59 | $2.89 |
| Indicator | SGC | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 44.50 | 38.13 |
| Support Level | $11.74 | $1.20 |
| Resistance Level | $12.35 | $2.49 |
| Average True Range (ATR) | 0.38 | 0.15 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 41.39 | 5.81 |
Superior Group Of Companies Inc designs apparel products. The company operates through three segments: i) The Branded Products segment, under the brands BAMKO and HPI, produces and sells customized merchandising solutions, promotional products, and branded uniform programs. ii) The Healthcare Apparel segment, under the brands Wink and Fashion Seal Healthcare, manufactures and sells healthcare apparel including scrubs, lab coats, protective apparel, and patient garments. iii) The Contact Centers segment, through The Office Gurus entities, provides outsourced, nearshore, and onshore business process outsourcing (BPO), contact center, and call-center support services to customers in North America. The majority of the company's revenue is derived from the Branded Products segment.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.